updated chart, page-2256

I think your assessment on news flow is very likely Dalts.

We know we are going to be getting PTX-200 readout in coming months.

The PTX-100 expanded cohort headline results before close of year is still target for CEO.

Stealth mode program, could be tomorrow or next month? But it's certainly not far off.

Further OmniCar optimisation trials were flagged by PTX management at time of last trial late last year.

So potentially the slow news months could be well behind us as we move into the next half of 2022?

There is a solid amount or serious data due out this year, data that could significantly move the sp and give PTX a much higher profile.

Then as we get into 2023, as OmniCar gets closer to arms that is hoped to happen around mid 2023....That will be nothing short of HUGE...A life changing moment for investors and hopefully cancer patients too.

Because or a few delays late last year, it may have worked very fortunately for shareholders...The biotech chart was on a one way trajectory, no matter what...Atleast now PTX-100 potentially has a plethora of significant data ready to blow the markets out of the water in close succession...A cluster bomb of announcements.

All extremely exciting for me personally, it's my favourite stock by far and the OmniCar IP is just so so cool...We are potentially holding the cure to cancer here.

Cheers.